Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lucky? Even nodummy did a deep dive on him and his scams.
Haven't looked yet, but I bet the company was dormant and most likely never a SEC registrant and or abandoned shell. We know wade doesn't like a company with a track record or real products.
Why is wade still walking the streets a free man?
Thanks. Looks like the company has been around but we know how Wade scams work.
They changed their name again and sector.
Think they're going to try another stock manipulation play so soon?
Yet another scam. No reverse split yet?
And don't worry, they will be announcing a covid cure soon.
Did the company even exist. Or perhaps even do anything the last 10 years and isn't dormant.
*check the intro page, someone inserted big red letters 2/3rds down inside your area with links to pump page.
Interesting. Have to put my DD cap on.
About Coeptis Therapeutics
Coeptis Therapeutics, Inc. (formerly Vinings Holdings Inc.), along with its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc. (together "Coeptis"), is a pharmaceutical company focused on the development of innovative therapeutics and technologies that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio consists of two clinical-stage drug candidates (CPT1550 and CPT60621), two approved drugs (Conjupri™ (levamlodipine) tablets and Consensi® (amlodipine and celecoxib) tablets), and the product opportunities through Coeptis' two exclusive option agreements with VyGen-Bio, Inc., for co-development rights to a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers which are being developed by VyGen-Bio. Coeptis' business model is designed around maximizing the value of its current product portfolio through in-license agreements, out-license agreements, and co-development relationships, as well as entering into strategic partnerships to expand its product portfolio in new and exciting therapeutic areas such as auto-immune disease and oncology. Coeptis is headquartered in Wexford, PA.
Owner (REGISTRANT) Conjupro Biotherapeutics Inc.
https://tmsearch.uspto.gov/bin/showfield?f=doc&state=4805:tqemkl.2.1
Burke Theraputics
https://burketherapeutics.com/conjupri-tablets
Vinings Holdings Inc., NDYN, changed to Coeptis Therapeutics Inc., COEP:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
$NDYN Coeptis Pharmaceuticals Enters into Exclusive Option Agreements with VyGen-Bio to Co-develop Technologies Designed to Improve the Treatment of CD38-Related Cancers
Press Release | 05/18/2021
Coeptis Pharmaceuticals Enters into Exclusive Option Agreements with VyGen-Bio to Co-develop Technologies Designed to Improve the Treatment of CD38-Related Cancers
Technologies being developed from VyGen-Bio's Gene-Edited Antibody Resistant NK (GEAR-NK) Platform
PR Newswire
WEXFORD, Pa., May 18, 2021
WEXFORD, Pa., May 18, 2021 /PRNewswire/ -- Coeptis Pharmaceuticals, Inc., a wholly-owned subsidiary of Vinings Holdings Inc. (OTC PINK: NDYN), today announced entry into two separate exclusive option agreements with VyGen-Bio, Inc., a majority-owned subsidiary of Vycellix, Inc., involving technologies being studied to potentially improve the treatment of CD38-related cancers. The technologies are CD38-GEAR-NK, a cell therapy product being developed to protect CD38+ natural killer (NK) cells from destruction by anti-CD38 monoclonal antibodies (mAbs), and CD38-Diagnostic, an in vitro diagnostic tool being developed to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. Both technologies are being developed from VyGen-Bio's Gene-Edited Antibody Resistant NK (GEAR-NK) platform, which was discovered by scientists at the Karolinska Institutet in Sweden.
The first option agreement involves co-development rights to CD38-GEAR-NK, which is an autologous, NK cell-based investigational therapeutic derived from a patient's own cells and gene-edited to enable combination therapy with anti-CD38 mAbs, potentially minimizing the risks and side effects from CD38-positive NK cell fratricide. The first indication is expected to be multiple myeloma, an incurable cancer of plasma cells. Per the option agreement, Coeptis has paid VyGen-Bio a non-refundable fee for the exclusive option to purchase the co-development rights to the technology. Coeptis has until December 31, 2021 to exercise the option and pay the specified exercise consideration.
The second option agreement involves co-development rights to CD38-Diagnostic, which is an investigational in vitro screening tool to potentially pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK. Per the option agreement, Coeptis has paid VyGen-Bio a non-refundable fee for the exclusive option to purchase the co-development rights to the technology. Coeptis has until December 31, 2021 to exercise the option and pay the specified exercise consideration.
"At Coeptis, we are focused on identifying and advancing technologies that have the potential to disrupt conventional treatment paradigms and improve patient outcomes," said Dave Mehalick, President and CEO of Coeptis Pharmaceuticals. "The option agreements with VyGen-Bio epitomize this business strategy as each technology may offer the potential to vastly improve the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, by identifying those patients who are most likely to benefit from anti-CD38 mAbs and then potentially 'super charging' a patient's immune system by protecting CD38+ NK cells from destruction by anti-CD38 mAbs."
Mr. Mehalick continued, "We envision these agreements with VyGen-Bio to be an important step in support of our focus in cell and gene therapy."
About Coeptis Pharmaceuticals
Coeptis Pharmaceuticals, Inc., a wholly-owned subsidiary of Vinings Holdings Inc. (OTC PINK: NDYN), is a pharmaceutical company focused on the development of innovative therapeutics and technologies that offer improvements to current therapies thereby improving patient outcomes. Coeptis' product portfolio consists of and two clinical-stage drug candidates – CPT1550 and CPT60621 – and two approved drugs – Conjupri™ (levamlodipine) tablets and Consensi® (amlodipine and celecoxib) tablets. Additionally, Coeptis recently entered into two exclusive option agreements with VyGen-Bio, Inc., Inc. for co-development rights to a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers which are being developed by VyGen-Bio. Coeptis' business model is designed around commercializing and furthering the development of its current product portfolio and maximizing the portfolio's value through in-license agreements, out-license agreements, and co-development relationships, as well as other strategic partnerships in new and exciting therapeutic areas such as auto-immune disease and oncology. Coeptis is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptispharma.com/.
Forward Looking Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited, to those risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules.
CONTACT
Tiberend Strategic Advisors, Inc.
Investors
Miriam Weber Miller
mmiller@tiberend.com
Media
David Schemelia
dschemelia@tiberend.com
Cision View original content:http://www.prnewswire.com/news-releases/coeptis-pharmaceuticals-enters-into-exclusive-option-agreements-with-vygen-bio-to-co-develop-technologies-designed-to-improve-the-treatment-of-cd38-related-cancers-301293485.html
SOURCE Coeptis Pharmaceuticals, Inc.
This obvious scam must now be higher on the SEC's list.
One down, about six more to go!
Stock is dead and it is by appointment only
Why didn’t the stock trade yesterday? Is there a suspension in the stock?
Lena Pharma is not listed at 1700 Somerset Ave. Looks like a scam address.
Remember Joseph Wade Mezey's wife, Tatania Shishove is a major share holder.
The building looks like one of many past ones claimed by Joseph Wade Mezey to be important/valuable.
https://rehold.com/Windber+PA/SOMERSET+AVE/1700
They just registered with the SEC on 2021-02-19 09:15:39.
https://sec.report/CIK/0001846888
The company was started in 2018. They just updated today, 2/24/2021.
HUGE RED FLAG!
Lisa Pharma, LLC and Lena Pharma are both at the same address. There are no records of an active company besides the names.
ANOTHER BIG RED FLAG.
Hold it and put away for $15-$20+ imo
https://www.nasdaq.com/market-activity/stocks/ndyn/sec-filings
13G filings on 2/19, Lena Pharma LLC & Lisa Pharma LLC
Something is up? Unfortunately, I sold all my shares at the beginning of last week. GLTA!
What is going on here?? I have had this stock since 2010 and wrote it off...wowza!
4.94 ? on very very low volume
boom whats commin hhmm
9K MOVES IT TO 2.50
Joe and Annie are laughing their azzes off.
NDYN $2.00s lets see where we go fun ride 4 sure
Insider enrichment.
All the details of share structure (from 8k) plus the Coeptis shares to be exchanged in the previous post.
I may be wrong but imo, still note a bad share structure
Section 6
(b) Capitalization.
(i) Acquisition Sub. Coeptis Acquisition Corp. has 1,000 shares of commons stock, par value $0.0001 per share, authorized, all of which are issued and outstanding and held by Vinings.
8
(ii) [u]VININGS’s authorized capital stock consists of (A) 750,000,000 shares of common stock, par value $0.0001 per share, 1,708,800 shares of Common Stock are issued and outstanding (2,708,800 common shares outstanding on a fully-diluted basis assuming conversion and exercise of all convertible and exercisable instruments) and (B) 10,000,000 shares of preferred stock, 8,000 shares of which are issued and outstanding as Series B Super Majority Voting Convertible Preferred stock (which such shares of Series B Super Majority Voting Convertible Preferred stock are convertible into 8,000,000 shares of Vinings common stock). All of the issued and outstanding shares of common stock and preferred stock of Vinings were duly and validly issued and fully paid, are non-assessable and free of preemptive rights, and were issued in compliance with all applicable state and federal securities laws.
(iii) Except as shown at Section 6(b) of the Vinings Disclosure Schedule, there are no outstanding (A) options, warrants, or other rights to purchase any capital stock of Vinings or Acquisition Sub; (B) debt securities or instruments convertible into or exchangeable for shares of any capital stock of Vinings or Acquisition Sub; or (C) commitments of any kind for the issuance of additional shares of capital stock or options, warrants or other securities of Vinings or Acquisition Sub.
(iv) Vinings owns all of the outstanding capital stock of Acquisition Sub, free and clear of all liens or other encumbrances.
Add in the Coeptis shares and still a low float:
(b) Effect on Capital Stock.
Conversion of Coeptis Shares. At the Closing, each Coeptis Share issued and outstanding on the Closing Date (as defined in Section 3, below) shall, by virtue of the Merger and without any further action on the part of Coeptis, Vinings, Acquisition Sub, or the holders of the Coeptis Shares as of the Closing Date (the “Original Holders”), be converted into and exchanged for one share of validly issued, fully paid and non-assessable common stock of Vinings (the “Share Ratio”) such that the Original Holders will be issued a total of twenty-five million one hundred and seventy-eight thousand eight hundred and forty (25,178,840) shares of common stock of Vinings (the “Vinings Common Stock”) as a result of the merger, and such shares shall be distributed pro rata to the holders of one hundred percent (100%) of the Coeptis common stock, subject to the receipt of letters of transmittal and any other documents required of the transfer agent; provided that the number of shares of Vinings Common Stock to be issued in connection with the Merger shall be increased on a one-for-one basis for each share of Coeptis Common Stock issued by Coeptis between the Effective Date and the Closing Date (which number of additional shares shall not exceed five million (5,000,000) without Vinings’ consent). All shares of Vinings Common Stock issued upon the exchange of Coeptis Shares in accordance with the terms hereof shall (i) contain a standard restricted securities legend in compliance with the Securities Act and (ii) be deemed to have been issued in full satisfaction of all rights pertaining to such Coeptis Shares. There shall be no further registration of transfers on the stock transfer books of Coeptis of the Coeptis Shares that were outstanding immediately prior to the Closing.
NDYN SECURITY DETAILS
Share Structure
Market Cap Market Cap
514,228
12/31/2020
Authorized Shares
750,000,000
11/30/2020
Outstanding Shares
1,658,800
11/30/2020
Restricted
1,250,400
11/30/2020
Unrestricted
408,400
11/30/2020
Something us definately up. Great close!
NDYN 400% and quite here, lol, must be all insiders buying
yea baby NDYN
yeap good lotto not really sure whats going in here yet
Liking it so far. Looks like 2+ soon
NDYN looking good $2.00 coming this week
NDYN still holding my handful for what ever
Best day so far
New company taking over ?
He is connected to the Russian scammers run by Mezey.
Erik S Nelson is a criminal and I wouldnt be surprised of he isnt behind most if not all of those 40 or so tickers that the SEC named in charges against 8 individuals for illegal WASH TRADING this past January.
The OTC penny market is infested with vermin like Nelson.
Erik S. Nelson, Chief Executive Officer - Mr. Nelson was disciplined by the NASD in 1995 for misconduct involving accounts
when he was acting as a registered broker representative. He consented to censure, and a
bar from being a representative, and was fined $50,000. He had been terminated as a
registered representative, and has not been reinstated since then.
https://backend.otcmarkets.com/otcapi/company/financial-report/245562/content
EDIT I did get the 200 shares on NOV 5th
So they changes course and filed months after the alleged change in control?
SMH
The filing is quite comical. Joseph Wad nMeezey's wife and Mother - in - law own controlling interest.
Do some real DD and see what happens to shells like this run by the family!
Nothing but insider enrichment. This should drop to .0001 rapidly!
Tatiana Shisohva is the mother of Anastasia Shishova.
https://www.sec.gov/Archives/edgar/data/1439208/000147793219003563/nydn_10-12g.htm
Here is some real DD about the players here and how they operate.
Joseph Wade’s Wife, Anastasia Shishova, Controlled Sunset Island Group.
SIGO withheld the relationship between its controlling officer at the time of the reverse-merger with Battle Mountain Genetics and Novus Group, LLC’s true owners, which included her husband, Joseph Wade.
Anastasia Shishova has been involved with two other penny stocks, including Buscar (OTC: CGLD) and Capall Stables (a shell with Joseph Wade as CEO), since 2012 . In May of 2016, a filing with Colorado’s Secretary of State indicates that she became the registered agent of SIGO. The first S-1 indicated that she was the sole executive officer:
On October 17, 2016, the Company entered into an Agreement whereby the Company acquired 100% of Battle Mountain Genetics, Inc, in exchange for 50,000,000 shares of Sunset Island Group common stock. Immediately prior to the reverse merger, there were 30,894 common shares outstanding and no shares of Preferred shares outstanding and Anastasia Shishova was the sole officer/director. After the reverse merger, the Company had 50,031,771 Common shares outstanding…
There was no disclosure whatsoever that Shishova is Wade’s wife, but another company’s SEC filing suggests that is the case. This is from an 8-K for Buscar Holdings (OTC: CGLD) announcing its new CEO and sole Director, Anastasia Shishova:
The day to day operations of the stable are managed by our trainer with Joseph Wade (Mr. Wade is the husband of our CEO) as the licensed person for the stable. Ms. Shishova is currently in the process of becoming the licensed individual.
This is a material relationship not disclosed by SIGO with respect to the controlling shareholder of Novus Group, LLC, which was registering 99.9% of the float (4mm shares) for sale, being married to the company’s sole officer and director at the time of its acquisition of Battle Mountain Genetics and the exchange of shares.
https://www.newcannabisventures.com/how-insiders-secretly-pocketed-3-million-from-sunset-island-group/
Here is a good read:
nodummy Wednesday, 09/27/17 02:13:09 PM
Re: surfkast post# 126993 0
Post #
127060
of 138455
SIGO is crazy isn't it. Based on my research I have come to the following conclusions:
Joseph Wade Mezey originally acquired the shell from David J Cutler making it the 5th shell sold by Cutler to Wade or one of Wade's associates (NHMD, VTXB, SGBY, OPMZ are the others). Joseph Wade Mezey's control of the SIGO shell was never disclosed in any SEC filings.
Joseph Wade Mezey placed his wife, Anastasia Shishova, as the CEO of SIGO after the acquisition but it has never disclosed to the public by SIGO about their relationship
Joseph Wade Mezey assisted in setting up Battle Mountain Genetics Inc paying Cheyenne Moseley of Legal Zoom to register the entity in California (same service provider he used to set up Novus Group LLC in Wyoming) then placed two of his former employees and long time business associates (TJ Magallanes and Valerie Baugher) as the executives for the new entity
Joseph Wade Mezey secretly controlled Novus Group LLC (with his buddy Matt Billington) but lied to the SEC about his control becoming the owner of 4,000,000 free trading shares of SIGO for the cost of $11,000
Joseph Wade Mezey merged his Novus Group LLC company into his OPMZ shell but after he had already pocketed about $700,000 (after taxes) and his buddy Matt Billington had pocketed $174,441 (after taxes) from their SIGO share sales. As part of the Novus Group LLC/OPMZ merger, OPMZ agreed to pay Joseph Wade Mezey and Matt Billington $150,000/month in "consulting fees" from any money made by Novus Group LLC in the future. It should be noted that the new SIGO executives (TJ Magallanes and Valerie Baugher) were formerly both employees of OPMZ through OPMZ's one time wholly owned subsidiary Von Baron Farms.
Novus Group LLC made approximately $1,300,000 more from its SIGO share sales after the OPMZ acquisition. Consulting fees paid out to Mezey and his buddy Matt Billington from that $1.3m would have come out to over $800,000. But $305,700 of the money made from those share sales was used by Novus Group LLC/OPMZ/Wade to lend to SIGO to help fund the SIGO business operations. To date SIGO hasn't disclosed in any SEC filings who the lender is - once again hiding Joseph Wade Mezey's involvement. It also sounds sort of illegal to me for money made from SIGO shares sales to be funneled back to SIGO to pay for the SIGO business operations without that plan being disclosed as part of the registration statement used to make those shares free trading.
Joseph Wade Mezey owns the lease to the greenhouse space that was subleased to SIGO but his name was never disclosed to the SEC by SIGO.
That $305,700 SIGO borrowed from Novus Group LLC/OPMZ/Wade was turned into 305,700 Series B shares ($1/share) which were going to pay out a $200/lb dividend (from cannabis sales) each quarter to be split among all the Series B preferred share holders. Obviously the only Series B preferred share holder would have been Novus Group LLC/Joseph Wade Mezey. SIGO never disclosed the name of the lender/Series B preferred share owner in any SEC filings once again hiding a Joseph Wade Mezey affiliation to SIGO.
That $200/lb dividend would have resulted in $150,000/month going into the pockets of Joseph Wade Mezey and Matt Billington as consulting fees (per the agreement between Novus Group LLC/Joseph Wade Mezey and OPMZ/Joseph Wade Mezey) with the rest staying with OPMZ.
SIGO mentioned a plan to sell Series B preferred shares to the public at $1,000/share in an 8K through what I'm pretty sure would have been an illegal share offering since they weren't registered. That would have been 1000 times more than Novus Group LLC/Wade got their shares for giving the purchaser(s) such a tiny percentage of the split that it would have been ridiculous.
It is interesting that they cancelled those Series B shares. Obviously there will be no lawsuit by the lender since Joseph Wade Mezey controls everything on both sides. I wonder if Joseph Wade Mezey cancelled them because he realized that his little gig is close to being up. Even though he tried hard to hide his involvement in everything, people that know how to do research were still able to figure it out. Not like it was hard. Joseph Wade Mezey likes to use the same addresses, same business associates, and same service providers repeatedly. He even makes the mistake of putting his own name on documents which can be found if people know where to look.
Joseph Wade Mezey/Novus Group LLC still secretly owns $305,700 in debt in SIGO. I'm sure that will eventually somehow result in SIGO revenues going into the pockets of Joseph Wade Mezey per the consulting agreement Wade has with Novus Group LLC/OPMZ.
My guess is that Joseph Wade Mezey is also the biggest investor to date in the 20,000,000 share offering at $.10/share and that most (if not all) of the 640,000+ shares dumped into the market to date through that offering went through the hands of Joseph Wade Mezey.... all while Joseph Wade Mezey has continued to hide his multiple affiliations to SIGO from the SEC.
This is the type of stuff that leads to much more than just SEC litigation. This is the type of stuff that could lead to a Criminal Indictment.
It will be very interesting to see where things go from here. Joseph Wade Mezey has been walking a fine line for years with his many many tickers and companies (some of the worst being GYST, STHC, EMBR, CGLD, NHMD, and OPMZ). And let's not forget his debt settlement scam he did Laura L Hess and Jeffrey Campos that got him disbarred in 2010.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134948820
Joseph Wade Mezey's Mother in law.
Tatiana Shishova 1,000,000 2,000,000
https://backend.otcmarkets.com/otcapi/company/financial-report/245562/content
Followers
|
110
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
11902
|
Created
|
03/04/10
|
Type
|
Free
|
Moderators |
"Coeptis Therapeutics is a biopharmaceutical
company developing innovative cell therapy
platforms for patients with cancer."
OUR MISSION:
"TO IMPROVE OUTCOMES FOR PATIENTS WITH CANCER"
Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen;
therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.
To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with
CD38 targeting therapies, and thus allowing tumor killing and immune surveillance.
Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and
maximize tumor kill via combinatorial approaches otherwise not possible.
Coeptis Therapeutics Holdings, Inc. conducts its commercial operations primarily through its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc.
Coeptis Therapeutics Holdings, Inc.
Corporate Headquarters
105 Bradford Road, Suite 420
Wexford, PA 15090
+1 (724) 934-6467
As of March 30, 2023 • 12:02 PM ET
As of March 30, 2023 • 12:02 PM ET
DATE/TIME | SOURCE | NEWS RELEASE |
---|---|---|
03/27/2023 10:47 AM EDT | SeekingAlpha | NBRV, JNCE and ALIM among healthcare movers |
03/27/2023 08:52 AM EDT | SeekingAlpha | IOVA, MQ and ONCS are among pre market gainers |
03/22/2023 08:30 AM EDT | InvestorBrandNetwork | InvestorNewsBreaks - Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) Tech Spotlighted in Article in Peer-Reviewed Translational Medicine Journal |
06/23/2022 05:27 PM EDT | SeekingAlpha | I-Mab Valuation Offers A Biotech Investment Opportunity |
04/22/2022 03:00 PM EDT | SeekingAlpha | Catalyst watch: Apple earnings, Twitter drama and media eyes on NAB Show |
04/19/2022 01:50 PM EDT | SeekingAlpha | Coeptis Therapeutics to merge with SPAC Bull Horn, uplist to Nasdaq |
04/13/2022 07:48 AM EDT | SeekingAlpha | Statera Biopharma stock soars 31% on potential drug platform acquisition by Coeptis Therapeutics |
05/18/2021 08:53 AM EDT | SeekingAlpha | Coeptis inks exclusive option agreements with VyGen-Bio |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for
information purposes only.
No stock exchange has approved or disapproved of the information here.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |